5MEDINA J,MORENO-OTERO R.Pathophysiological basis for antioxidant therapy in chronic liver disease[J].Drugs,2005,65:2445-2461.
6LIEBER CS,LEO MA,CAO Q,et al.Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons[J].J Clin Gastroenterol,2003,37:336-339.
7MURRAY KF,CARITHERS RL.AASLD practice guidelines:Evaluation of the patient for liver transplantation[J].Hepatology,2005,41:1407-1432.
8LOK AS,MCMAHON BJ.Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations[J].Hepatology,2004,39:857-861.
9SANYAL AJ.American Gastroenterological Association technical review on nonalcoholic fatty liver disease[J].Gastroenterology,2002,123:1705-1725.
10GRAILF M,YANUKA M,BARAZ M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease[J].Invest Radiol,2000,35:319-324.
